Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M144,497Revenue $M44,408Net Margin (%)11.2Z-Score2.3
Enterprise Value $M158,775EPS $1.9Operating Margin %15.3F-Score5
P/E(ttm))26.8Cash Flow Per Share $0Pre-tax Margin (%)13.8Higher ROA y-yY
Price/Book2.110-y EBITDA Growth Rate %8.2Quick Ratio1.0Cash flow > EarningsY
Price/Sales3.45-y EBITDA Growth Rate %-1.6Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %9.0ROA % (ttm)3.9Higher Current Ratio y-yN
Dividend Yield %3.5Insider Buy (3m)0ROE % (ttm)6.5Less Shares Outstanding y-yN
Payout Ratio %89.0Shares Outstanding M2,649ROI % (ttm)4.2Gross Margin Increase y-yN

Gurus Latest Trades with SNY

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYPRIMECAP Management 2014-06-30 Add0.03%$51.23 - $54.54
($53.08)
$ 54.73%Add 21.59%3,011,646
SNYScott Black 2014-06-30 Reduce-0.39%$51.23 - $54.54
($53.08)
$ 54.73%Reduce -27.57%178,985
SNYJohn Hussman 2014-06-30 Sold Out -0.09%$51.23 - $54.54
($53.08)
$ 54.73%Sold Out0
SNYScott Black 2014-03-31 Buy 1.4%$47.77 - $53.63
($50.64)
$ 54.78%New holding, 247100 sh.247,100
SNYJames Barrow 2014-03-31 Add0.39%$47.77 - $53.63
($50.68)
$ 54.78%Add 22.72%27,790,116
SNYCharles Brandes 2013-12-31 Add0.2%$48.75 - $54
($51.57)
$ 54.76%Add 18.29%2,013,300
SNYMario Gabelli 2013-12-31 Reduce$48.75 - $54
($51.57)
$ 54.76%Reduce -24.37%4,500
SNYJames Barrow 2013-09-30 Add1.29%$47.64 - $53.24
($50.87)
$ 54.78%Add 312.86%21,466,988
SNYMario Gabelli 2013-09-30 Add$47.64 - $53.24
($50.87)
$ 54.78%Add 32.22%5,950
SNYMario Gabelli 2013-06-30 Buy $49.77 - $55.64
($53.28)
$ 54.73%New holding, 4500 sh.4,500
SNYCharles Brandes 2013-06-30 Reduce-0.26%$49.77 - $55.64
($53.28)
$ 54.73%Reduce -20.35%1,713,266
SNYCharles Brandes 2012-09-30 Reduce-0.41%$36.81 - $44.6
($40.57)
$ 54.735%Reduce -25.37%2,982,819
SNYDavid Dreman 2012-09-30 Sold Out -0.09%$36.81 - $44.6
($40.57)
$ 54.735%Sold Out0
SNYJohn Hussman 2012-06-30 Add$33.4 - $39.06
($35.98)
$ 54.752%Add 22.62%27,100
SNYPRIMECAP Management 2012-03-31 Add0.08%$35.32 - $38.92
($35.05)
$ 54.756%Add 141.26%2,222,692
SNYJames Barrow 2011-12-31 Add0.08%$31.72 - $37.45
($34.48)
$ 54.759%Add 26.83%4,501,475
SNYGeorge Soros 2011-12-31 Sold Out -0.11%$31.72 - $37.45
($34.48)
$ 54.759%Sold Out0
SNYJames Barrow 2011-09-30 Add0.13%$31.5 - $40.08
($35.94)
$ 54.752%Add 83.96%3,549,200
SNYGeorge Soros 2011-09-30 Buy 0.11%$31.5 - $40.08
($35.94)
$ 54.752%New holding, 201400 sh.201,400
SNYDodge & Cox 2011-06-30 Add0.16%$35.68 - $40.58
($38.04)
$ 54.744%Add 6.63%54,287,695
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SNY PRIMECAP Management 2014-06-303,011,6460.110.18+21.59%
SNY Charles Brandes 2014-06-302,182,3050.081.4+5.28%
SNY James Barrow 2014-06-3028,526,8021.082+2.65%
SNY Mario Gabelli 2014-06-304,50000
SNY Warren Buffett 2014-06-303,905,8750.150.19
SNY Dodge & Cox 2014-06-3043,549,9091.642.2-0.26%
SNY Jean-Marie Eveillard 2014-06-30608,5680.020.08-0.36%
SNY Scott Black 2014-06-30178,9850.011.4-27.57%
SNY John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2014-03-25Buy344,448$66.88-18.21view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67613.17view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      The French Government Collapses…and French Stocks Rally. What Gives? Aug 26 2014 
      Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
      Sanofi Doesn´t Look Good in Absolute Valuation Method Aug 21 2014 
      How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
      Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
      George Soros Reveals His Largest Stake Jul 23 2014 
      Health Care Sector in an Upward Climb in June Jun 12 2014 
      Sarah Ketterer’s Causeway International Value’s Top Five Holdings Jun 05 2014 
      Top Held European Stocks Highlighted by Health Care and Oil and Gas Stocks May 29 2014 
      Oakmark's Bill Nygren Discusses Financials, Favorite Stocks Apr 15 2014 


      More From Other Websites
      Regeneron Pharmaceuticals' Pipeline Progress Raises Costs Aug 29 2014
      Amgen: Why Its New Drug Application is a Big Deal Aug 28 2014
      There Are 2000 Reasons For Continued Optimism In The Stock Market Aug 28 2014
      The Zacks Analyst Blog Highlights: RadioShack, Amicus Therapeutics, Sanofi, Shire and Gilead... Aug 28 2014
      Where Are the Opportunities in U.S. Health Care? Aug 27 2014
      Return to Behemoth Stocks Aug 27 2014
      The 4 Companies Teaming Up For A New Tool To Fight Cancer Aug 25 2014
      InterMune Stock Spikes On Rare Big Biotech Buyout Aug 25 2014
      Regeneron and Sanofi to Present Results from Four Phase 3 Alirocumab Trials in Hot Line Session at... Aug 25 2014
      Covance Retains Balanced View on Steady Growth Aug 22 2014
      AstraZeneca Updates on PLATO Study Investigation on Brilinta Aug 22 2014
      Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day Aug 22 2014
      Amicus Therapeutics (FOLD) Soars on Fabry Drug Trial Results Aug 21 2014
      5 companies that will benefit from ALS awareness Aug 21 2014
      Illumina Partners with AstraZeneca, Sanofi, Janssen in NGS Aug 21 2014
      Video: Illumina Partners With Big Pharma Firms Aug 21 2014
      Illumina Partners With Big Pharma To Create New Genetic Tests For Cancer Aug 21 2014
      Sanofi's (SNY) Cerdelga FDA Approved for Gaucher Disease Aug 20 2014
      Amicus Releases Positive Study Results On Rare Disease Drug Aug 20 2014
      Yes, Call it a Comeback: Amicus Fabry Drug Posts Big Study Win Aug 20 2014
      FDA Approves Genzyme’s Cerdelga™ (eliglustat) Capsules Aug 19 2014
      Eli Lilly-Boehringer's Insulin Drug Gets Tentative FDA Nod Aug 19 2014
      Sanofi and Regeneron To Present Alirocumab Clinical Data at American College of Cardiology 63rd... Mar 27 2014
      Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's... Mar 27 2014
      Sanofi Pasteur Allies with SK Chemical Co. of South Korea on Pneumococcal Conjugate Vaccine Mar 19 2014
      Sanofi and UCB Partner for Breakthrough Innovation in Immune-mediated Diseases Mar 11 2014
      Filing of the 2013 U.S. Form 20-F and French “Document de Référence” containing the Annual... Mar 07 2014
      Inactivated Polio Vaccines Broadly Available for the World’s Children in the Drive toward Polio... Feb 28 2014
      A*STAR, NUS and NUH Join Forces to Understand Immune Erosion in Elderly Feb 12 2014
      “India’s vast polio achievement is a call for action for all of us” says Sanofi Pasteur CEO Feb 11 2014
      Sanofi Files Suit in The U.S. To Defend Its Patent Rights on Lantus® and Lantus® SoloStar® Jan 31 2014
      RobecoSAM Includes Sanofi in “Silver Class” of its 2014 Sustainability Yearbook Jan 30 2014
      Sanofi and Transgene Launch Construction Phase of New State-of-the-art Bioproduction Platform Jan 29 2014
      Sanofi and Fraunhofer-Gesellschaft Announce the Creation of a Natural Product Center of Excellence Jan 15 2014
      Genzyme and Alnylam Expand Collaboration on Rare Genetic Diseases Jan 13 2014
      Sanofi To Expand Access to Clinical Trial Data Jan 02 2014
      Genzyme Receives Complete Response Letter from FDA on Lemtrada™ (alemtuzumab) Application Dec 30 2013
      Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor... Dec 19 2013
      Sanofi and Regeneron Announce Collaboration with American College of Cardiology for PCSK9 Inhibitor... Dec 19 2013
      Merial Receives EMA approval for Broadline™ for Broad Spectrum Parasite Treatment and Prevention... Dec 12 2013
      FDA Grants Priority Review for Genzyme’s Cerdelga™ (eliglustat), an Investigational Oral Therapy... Dec 11 2013
      New Data Support Flexibility in Timing of Administration for Sanofi’s Lyxumia® Dec 05 2013

      Add Notes, Comments or Ask Questions

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK